Femasys
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Georgia, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3950 Johns Creek Ct Ste 100, Suwanee, Ge...Phone Number
(877) 336-2562Website
www.femasys.comRevenue
<$5 MillionStock Symbol
FEMYIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Femasys
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare prRead more
Femasys Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Femasys your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Femasys, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Femasys has new funding data
Click to see if Femasys had a recent Job posting/layoffs
Earning: See what the market has to say on Femasys recently announced quarterly report
Check out if Femasys is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Femasys
Product Launch: Get notified when Femasys launches new products
Check if Femasys has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Femasys
Compare insights from companies similar to Femasys, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Femasys is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Femasys is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Femasys.
Femasys financials insights
Gather financial insights about Femasys, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Private Equity
$641K
Unspecified
$1.8M
2012
Private Equity
$1M
2015
Series B
$10.2M
2016
Private Equity
$3.3M
Series C
$40M
2020
Debt
$350K
2023
Other Financing Round
$5M
2025
Stock/Share Issuance
$10M
Stock/Share Issuance
$12M
Femasys Tech Stack
A closer look at the technologies used by Femasys
Most Recent Scoops
Person-Based
Compliance
Person-Based
Earnings, Finance
Person-Based
Earnings, Finance
Person-Based
Kathy Lee-Sepsick fertility portfolio and allows OB/GYNs to offer more in-office fertility services.
Doctors / Physicians
Person-Based
Product Launch
Femasys News & Media
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its finaFemasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the issuance of patents in the United States and key internFemasys Inc (FEMY) CTO buys stock and receives milestone-based warrants
Femasys CTO Jeremy Sipos bought 3,125 shares at $3.20 and received two 3,125-share warrants at $2.95, including a milestone warrant tied to $1,500,000 U.S. quarterly revenue and stock price conditions.Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has entered into a securities purchase agreement (the “Purchase Agreement”) for a $30 million private placement
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Femasys
Sign Up For FreeTo access detailed company insights
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product... Read More
